Investing.com -- Bank of America upgraded Moderna to Neutral with a $170 price objective, following a sharp rally in the stock after positive data on its personalized cancer vaccine, intismeran, in adjuvant melanoma.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
143last 24h
876last 7d
147● bullish (7d)
98● bearish (7d)
214publishers
Investing.com35d agobullish
BofA upgrades Moderna after 177% rally driven by cancer vaccine breakthrough